Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05280014 vs Herceptin in Neoadjuvant HER2+ Breast Cancer
NCT02187744Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of trastuzumab-qyyp in HER2-positive breast cancer, sponsored by Pfizer. Started Sep 2014; status: completed.
02
Drugs
trastuzumab-qyyp
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02187744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187744.